NCT05092373
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Breast Carcinoma, +110 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Stage III Primary Peritoneal Cancer AJCC v8
Explore clinical trials studying Stage III Primary Peritoneal Cancer AJCC v8. Study availability and eligibility vary by location and protocol.
10 public trials
3 recruiting studies
Stage III Primary Peritoneal Cancer AJCC v8 trial results
NCT05415709
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +47 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +30 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Active, Not Recruiting
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
NCT04616534
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
- Locations
-
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
Active, Not Recruiting
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
NCT02650986
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +78 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Active, Not Recruiting
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +26 more
- Locations
-
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
Active, Not Recruiting
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
NCT03943173
- Conditions
- Adnexal Diseases, BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, +45 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT04673448
- Conditions
- Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, +53 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
NCT05276973
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +32 more
- Locations
-
- UCSF Medical Center-Mission Bay San Francisco, California, United States
- Augusta University Medical Center Augusta, Georgia, United States
- Cleveland Clinic Foundation Cleveland, Ohio, United States
- University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States
Active, Not Recruiting
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03907527
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +48 more
- Locations
-
- National Institutes of Health (NIH) Bethesda, Maryland, United States
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States